BioWorld MedTech

Nov. 15, 2013

View Archived Issues

Svelte enrolls final patient in DIRECT II clinical study

Svelte Medical Systems (New Providence, New Jersey) reported the enrollment of the final patient in the DIRECT II (Direct Implantation of Rapamycin-Eluting stents with bioabsorbable drug Carrier Technology) clinical study. Read More

Chinese orthopedic company initiates IPO in Hong Kong

Read More

International report: AirXpanders gets Australian approval for its AeroForm

Read More

Washington roundup: FDA approves NeuroPace RNS for refractory epilepsy

Read More

Court report: J&J looking at $4 billion settlement regarding ASR

Read More

Financings roundup: Tandem Diabetes Care prices IPO at $15/share

Read More

Patent watch: Neovasc gets protection for Tiara valve prosthesis

Read More

Agreements/contracts: Visualant and IV to accelerate ChromaID tech applications

Read More

Deals roundup: PositiveID sells interest in VeriTeQ for $750,000

Read More

People in the News

Read More

Product Briefs

Read More

Med-Tech Notes

Read More

MDD's Diagnostic Extra

Read More